BlackRock Finance, Inc. - SUPERNUS PHARMACEUTICALS INC ownership

SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 239 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.

Quarter-by-quarter ownership
BlackRock Finance, Inc. ownership history of SUPERNUS PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2024$278,003,014
-21.3%
10,392,636
+0.3%
0.01%
-25.0%
Q1 2024$353,459,964
+17.6%
10,362,356
-0.2%
0.01%0.0%
Q4 2023$300,477,364
+7.1%
10,382,770
+2.0%
0.01%0.0%
Q3 2023$280,659,981
-6.3%
10,179,905
+2.2%
0.01%0.0%
Q2 2023$299,410,317
-13.0%
9,960,423
+4.9%
0.01%
-20.0%
Q1 2023$344,162,173
+0.5%
9,499,370
-1.1%
0.01%
-9.1%
Q4 2022$342,606,497
+9.8%
9,604,892
+4.2%
0.01%0.0%
Q3 2022$311,983,000
+22.6%
9,216,574
+4.8%
0.01%
+37.5%
Q2 2022$254,383,000
-11.5%
8,796,145
-1.1%
0.01%0.0%
Q1 2022$287,311,000
+16.6%
8,889,575
+5.2%
0.01%
+33.3%
Q4 2021$246,431,000
+4.3%
8,451,022
-4.6%
0.01%
-14.3%
Q3 2021$236,263,000
-13.5%
8,858,737
-0.2%
0.01%
-12.5%
Q2 2021$273,171,000
+16.0%
8,872,052
-1.4%
0.01%
+14.3%
Q1 2021$235,467,000
+5.0%
8,994,226
+0.9%
0.01%0.0%
Q4 2020$224,247,000
+18.5%
8,912,801
-1.8%
0.01%0.0%
Q3 2020$189,214,000
-10.5%
9,079,322
+2.0%
0.01%
-12.5%
Q2 2020$211,475,000
+37.4%
8,904,300
+4.1%
0.01%0.0%
Q1 2020$153,893,000
-25.7%
8,554,255
-2.1%
0.01%0.0%
Q4 2019$207,191,000
-9.1%
8,734,832
+5.4%
0.01%
-20.0%
Q3 2019$227,813,000
-15.9%
8,290,127
+1.2%
0.01%
-16.7%
Q2 2019$270,995,000
-4.0%
8,189,577
+1.7%
0.01%
-7.7%
Q1 2019$282,248,000
+5.2%
8,055,030
-0.3%
0.01%
-7.1%
Q4 2018$268,272,000
-33.4%
8,075,659
+0.9%
0.01%
-17.6%
Q3 2018$402,951,000
-12.5%
8,003,001
+4.1%
0.02%
-19.0%
Q2 2018$460,287,000
+42.1%
7,690,669
+8.7%
0.02%
+40.0%
Q1 2018$323,898,000
+17.8%
7,071,947
+2.5%
0.02%
+15.4%
Q4 2017$275,054,000
+1.4%
6,902,230
+1.8%
0.01%
-7.1%
Q3 2017$271,272,000
-6.4%
6,781,836
+0.8%
0.01%
-6.7%
Q2 2017$289,962,000
+38.3%
6,727,641
+0.5%
0.02%
+25.0%
Q1 2017$209,595,000
+192189.0%
6,696,310
+156173.3%
0.01%
Q4 2016$109,000
-6.0%
4,285
-8.6%
0.00%
Q3 2016$116,000
+19.6%
4,688
-1.1%
0.00%
Q2 2016$97,000
+148.7%
4,742
+81.8%
0.00%
Q1 2016$39,000
+178.6%
2,608
+156.9%
0.00%
Q4 2015$14,000
+55.6%
1,015
+54.5%
0.00%
Q3 2015$9,000
-18.2%
6570.0%0.00%
Q2 2015$11,000
+22.2%
657
-14.3%
0.00%
Q1 2015$9,000
+50.0%
7670.0%0.00%
Q4 2014$6,000
-14.3%
7670.0%0.00%
Q3 2014$7,000
-12.5%
7670.0%0.00%
Q2 2014$8,0007670.00%
Other shareholders
SUPERNUS PHARMACEUTICALS INC shareholders Q2 2024
NameSharesValueWeighting ↓
ASHFORD CAPITAL MANAGEMENT INC 826,488$23,918,5633.20%
ARMISTICE CAPITAL, LLC 4,650,000$134,571,0001.84%
Seaport Global Advisors, LLC 16,069$465,0371.11%
Aristotle Capital Boston, LLC 1,159,828$33,565,4191.03%
S&T BANK/PA 189,356$5,4801.01%
RICE HALL JAMES & ASSOCIATES, LLC 529,952$15,336,8110.89%
Bridge City Capital, LLC 78,675$2,276,8550.88%
Tributary Capital Management, LLC 346,261$10,020,7930.84%
Bruce & Co., Inc. 82,105$2,376,1190.83%
Stephens Investment Management Group LLC 1,904,864$55,126,7640.81%
View complete list of SUPERNUS PHARMACEUTICALS INC shareholders